세계의 수막염균 백신 시장 규모는 2022년에 43억 달러로 평가되며, 2023년 45억 8,000만 달러에서 2031년에는 75억 8,000만 달러로 성장하며, 예측 기간 중(2024-2031년) CAGR은 6.5%로 성장할 전망입니다.
수막염균 백신 시장은 CDC가 보고한 바와 같이 전 세계에서 약 120만 건에 달하는 수막염 발병률 증가에 힘입어 큰 성장이 예상됩니다. 예방접종 구상 강화, 대중의 인식 개선, 수막구균 백신에 대한 연구개발 활동의 활성화는 시장 확대를 더욱 촉진할 것으로 예상됩니다. 미국수막염협회(National Meningitis Association)와 수막염연구재단(Meningitis Research Foundation)과 같은 단체가 주도하는 수많은 캠페인이 인지도를 높이고 혁신적인 예방 전략을 추진하고 있습니다. 수막염균을 표적으로 하는 백신은 A, B, C, W-135, Y 균주에 대한 단일가 및 다중가 옵션 등 다양한 백신이 시장에 나와 있습니다. 또한 엄격한 규제 조치로 인한 잠재적 문제에도 불구하고 국가 예방접종 프로그램에 이들 백신의 통합이 진행되고 있으며, 여행용 백신 접종의 가용성이 확대되고 있는 것이 시장 역학에 영향을 미치는 주요 요인으로 작용하고 있습니다.
Global Meningococcal Vaccines Market size was valued at USD 4.30 billion in 2022 and is poised to grow from USD 4.58 billion in 2023 to USD 7.58 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2024-2031).
The meningococcal vaccines market is poised for significant growth, driven by the rising incidence of meningitis, with an estimated 1.2 million cases globally, as reported by the CDC. Enhanced immunization initiatives, heightened public awareness, and intensified research and development activities surrounding meningococcal vaccines are expected to further bolster market expansion. Numerous campaigns led by organizations like the National Meningitis Association and the Meningitis Research Foundation are raising awareness and promoting innovative prevention strategies. The market features various vaccines targeting Neisseria meningitidis, including monovalent and multivalent options against strains A, B, C, W-135, and Y. Additionally, the increasing integration of these vaccines into national immunization programs and the growth of travel vaccination availability are key factors influencing market dynamics, despite potential challenges from strict regulatory measures.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Meningococcal Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Meningococcal Vaccines Market Segmental Analysis
Global Meningococcal Vaccines Market is segmented by vaccine type, brand, age group, end user and region. Based on vaccine type, the market is segmented into polysaccharide vaccines, conjugate vaccines (quadrivalent, bivalent, monovalent), combination vaccines and men b vaccines. Based on brand, the market is segmented into menactra, menveo, nimenrix, bexsero, trumenba and others. Based on age group, the market is segmented into infants, children, adolescents and adults. Based on end user, the market is segmented into hospitals, clinics, vaccination centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Meningococcal Vaccines Market
A significant factor propelling the global meningococcal vaccines market is the growing incidence of meningococcal diseases worldwide. The emergence of meningitis and septicemia caused by Neisseria meningitidis presents a serious health threat, resulting in high mortality rates and potential long-term consequences, including neurological damage. Consequently, healthcare providers are increasingly focusing on preventive measures, particularly vaccination, to curb these outbreaks. This concern is particularly pronounced in specific regions, such as Sub-Saharan Africa, often referred to as the "meningitis belts," where the prevalence of infections is notably higher, thereby driving the demand for effective vaccines in these vulnerable areas.
Restraints in the Global Meningococcal Vaccines Market
A significant restraint within the global meningococcal vaccines market is the prohibitively high production and distribution costs. The advanced vaccines, particularly those utilizing conjugate and recombinant technologies, are not easily accessible in low-income regions that are disproportionately affected by meningococcal disease. Despite efforts from governmental and non-governmental organizations to provide subsidies, the overall affordability of these vaccines continues to pose a major challenge. This financial barrier ultimately limits the reach of vaccination programs, hindering efforts to achieve broad immunization coverage and protect vulnerable populations from the potentially devastating impacts of meningococcal infections.
Market Trends of the Global Meningococcal Vaccines Market
The global meningococcal vaccines market is witnessing a significant trend towards the adoption of combination vaccines, particularly quadrivalent formulations that provide protection against serogroups A, C, W, and Y. This preference is largely driven by the advantages these vaccines offer, including wider coverage and the convenience of requiring fewer doses. As healthcare systems aim to improve immunization rates and streamline vaccine administration processes, combination vaccines are becoming essential in overcoming logistical hurdles and enhancing patient adherence to vaccination schedules. This trend not only reflects a growing awareness of meningococcal disease but also represents a pivotal shift towards more effective public health strategies.